Jazz Pharmaceuticals: Analyst Forecasts After Q2 Earnings
Table of Contents
Last week, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its second-quarter results. The initial market reaction was negative, with shares falling 3.7% to US$111 in the past week. The results were largely disappointing; revenues met expectations at US$1.0b, but statutory losses surged to US$11.74 per share. This is a crucial time for investors to assess the company’s performance, review expert forecasts, and identify any shifts in expectations.
We’ll examine the latest analyst (statutory) post-earnings forecasts for the coming year.
Revenue Expectations for 2025
Currently, the 18 analysts covering Jazz Pharmaceuticals predict revenues of US$4.21b in 2025. This represents a projected 3.1% increase compared to the previous 12 months.
Analysts anticipate a meaningful increase in per-share losses, forecasting US$7.88. Though, it’s vital to note that prior to the earnings release, forecasts were for revenues of US$4.23b and losses of US$8.50 per share in 2025.
Shift in Analyst Sentiment
The recent updates suggest a slight enhancement in analyst sentiment. While revenue expectations remain relatively stable,analysts have become somewhat more optimistic regarding projected losses per share.
Key Takeaways
- Jazz Pharmaceuticals reported disappointing Q2 results with significant losses.
- Analysts forecast US$4.21b in revenue for 2025, a 3.1% increase.
- Projected losses per share are US$7.88 for 2025.
- Analyst sentiment has slightly improved since the earnings release, particularly regarding loss projections.
Publication Date: 2025/08/09 16:25:13